{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093888","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.741125+00:00","generated_at":"2026-05-31T11:10:52.251516+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioAtla Q2 net loss $21.1M; cash to Q3 2025; Fast Track for ozuriftamab vedotin","bullets":["Net loss of $21.1M for Q2 2024 vs $35.8M in Q2 2023; R&D expenses fell to $16.2M from $31.0M.","Cash and equivalents $61.7M as of June 30, 2024, expected to fund operations through Q3 2025.","Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track by FDA for SCCHN; FDA meeting for registrational trial expected in 2H 2024.","Mecbotamab vedotin (CAB-AXL-ADC) Phase 2 in NSCLC shows OS trend in mutated KRAS; responses across G12A, G12C, G12V.","Evalstotug (CAB-CTLA-4) combined Phase 1/2 safety: low grade 3 irAEs (4/40); Phase 2 melanoma data on track for 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093888","json":"https://secwatch.observer/filing/0000950170-24-093888.json","markdown":"https://secwatch.observer/filing/0000950170-24-093888.md","text":"https://secwatch.observer/filing/0000950170-24-093888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000095017024093888/0000950170-24-093888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000095017024093888/bcab-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:10:52.251516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}